SMMT Summit Therapeutics
- 4.780
- -0.180-3.63%
- 4.800
- +0.020+0.42%
Summit Therapeutics News
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday.Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply during Tuesday's session following upbeat quarterly ear
Summit Therapeutics (SMMT.US) was first covered by Citi, giving it a buy rating, with a target price of $7.00.
Summit Therapeutics (SMMT.US) was first covered by Citi, giving it a buy rating, with a target price of $7.00.
Summit Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 55.56% Citigroup → $7 Initiates Coverage On → Buy 03/26/2024 77.78% Stifel → $8 Initiates Cover
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q1 2024 Earnings Conference
The following is a summary of the Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript:Financial Performance:Summit Therapeutics ended Q1 2024 with a cash balance of $157 million, projecte
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, and Iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.4
Ventyx Biosciences closed 25.13%, leading Summit Therapeutics Plc. , Cabaletta Bio, Wave Life Sciences, Xencor, Humacyte, and BioCryst Pharmaceuticals rose 19.59%-10.65%, iteos rose 9.82%; SAGE Therapeutics closed down 4.73%, Tango Therapeutics fell 5.45%, and Alexis fell 6.54
Summit Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.
Summit Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.
Summit Therapeutics Q1 EPS $(0.06) Up From $(1.43) YoY; Exits Q1 With Cash & Equivalents Worth $157M
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.06) per share. This is a 95.8 percent increase over losses of $(1.43) per share from the same period last year.
Summit Therapeutics 1Q Loss/Shr 6c >SMMT
Summit Therapeutics 1Q Loss/Shr 6c >SMMT
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2024 financial results and provide an operational update for the Company on Wednesday, May 1, 2024, before the market opens.
Daily rights tracking | Bitcoin hits 67,000 US dollars, crypto mining companies are in high demand
Tesla surged more than 12% before the market, and overnight options traded 1.75 million, with a bearish ratio of 55.2%. More than 53,000 PUT transactions due on Friday with an exercise price of 140 US dollars topped the list.
Daily rights tracking | Trump's media rose 40% in two days! Earn eight times the option premium with a single call
Tesla's multiple single options due today doubled and surged; TSMC options trading volume surged by nearly 60%, slightly rising to 68% from a bullish ratio.
Summit Therapeutics Appoints Biotech Veteran to Board
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to Its Board of Directors
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Summit Therapeutics (SMMT) and Neurocrine (NBIX)
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief Financial Officer, Dave Gancarz, Chief Business & Strategy Officer, and Dr. Allen S. Yang, Chief Medical Officer, will participate in a fireside chat on behalf of our organization surrounding the development of our innovative investigational bispecific antibody, ivonescimab, on Tuesday April 16, 2024 at 2:30pm ET.
UPDATE 2-Illumina CFO Goswami to Depart, Former Summit Therapeutics Exec Dhingra to Succeed
Illumina Appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to...
Summit Therapeutics Shares Are Trading Lower After the Company Announced a Leadership Restructuring.
Summit Therapeutics Shares Are Trading Lower After the Company Announced a Leadership Restructuring.
Summit Therapeutics Appoints COO to Additional Role of CFO
Summit Therapeutics (SMMT) said in a Wednesday regulatory filing that Ankur Dhingra resigned as chief financial officer of the company on April 2. The company appointed Chief Operating Officer Manmeet
Summit Therapeutics Announces Major Leadership Restructuring
Analysis
Price Target
No Data
